piwik-script

English Intern
    Lehrstuhl für klinische Epidemiologie und Biometrie

    UNITI

    Unification of treatments and Interventions for Tinnitus patients

    Koordinator UNITI :

    Winfried Schlee, Universität Regensburg, Deutschland

    Koordination des WP 4 (Harmonisierung technischer Lösungen):

    Prof. Rüdiger PryssCarsten Vogel

    Founder:

    European Union Research and Innovation programme Horizon 2020

    Status:

    Dauer 39 Monate, Start Datum 01 Jan 2020, grant number 848261

     

    Beschreibung

    Tinnitus is the perception of a phantom sound and the patient’s reaction to it. Tinnitus remains a scientific and clinical enigma of iTinnitus is the perception of a phantom sound and the patient’s reaction to it. Although much progress has been made, tinnitus remains a scientific and clinical enigma of high prevalence and high economic burden. It affects more than 10% of the general population, whereas 1% of the population considers tinnitus their major health issue. Recent cohort studies show that tinnitus prevalence tends to increase over time and with older age. Assuming that there is no cure to be found, the prevalence estimates in Europe would double by 2050. A large variety of patient characteristics - including genotyping, aetiology, and phenotyping - are poorly understood, because integrated systems approaches are still missing to correlate patient`s characteristics to predict responses to combinatorial therapies.

    Although genetic causes of tinnitus have been neglected for decades, recent findings of genetic analysis in specific subgroups (gender and phenotype) have highlighted that bilateral tinnitus in men reached a heritability of 0.68. This heritability is close to autism, schizophrenia and Attention Deficit Hyperactive Disorder (ADHD). There is no current consensus on tinnitus treatment. UNITI’s overall aim is to deliver a predictive computational model based on existing and longitudinal data attempting to address the question which treatment approach is optimal for a specific patient based on specific parameters. Clinical, epidemiological, medical, genetic and audiological data, including signals reflecting ear-brain communication, will be analysed from existing databases. Predictive factors for different patient groups will be extracted and their prognostic relevance will be tested in a randomized controlled trial (RCT) in which different groups of patients will undergo a combination of therapies targeting the auditory and central nervous systems.

    Arbeitspakete

    Arbeitspaket Inhalt Verantwortung
    WP1 Ethics University of Regensburg (UHREG)
    WP2 Project Management University of Regensburg (REG)
    WP3 Analysis of existing data University of Magdeburg (MAG)
    WP4 Harmonization of technical solutions Julius-Maximilians-Universität Würzburg (JMU)
    WP5 Intelligent data analysis ICCS
    WP6 Genetics GRA
    WP7 Randomized Clinical Trial University of Regensburg (REG)
    WP8 Dissemination, Communication and Exploitation VIL

     

    Übersicht

    UNITI Workpackages Overview

    Partner

    Nr Name Abkürzung Land Projekteintrittsmonat Projektabschlussmonat

    1.

    KLINIKUM DER UNIVERSITAET REGENSBURG UHREG

    Deutschland

    1 39

    2.

    KATHOLIEKE UNIVERSITEIT LEUVEN KUL Belgien 1 39

    3.

    ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON UOA Griechenland 1 39

    4.

    CHARITE - UNIVERSITAETSMEDIZIN BERLIN

    CHA

    Deutschland 1 39

    5.

    SERVICIO ANDALUZ DE SALUD

    GRA

    Spanien 1 39

    6.

    KAROLINSKA INSTITUTET

    KI

    Schweden 1 39

    7.

    OTTO-VON-GUERICKE-UNIVERSITAET MAGDEBURG

    MAG

    Deutschland 1 39

    8.

    UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS- UNIVERSITAET

    JMU

    Deutschland 1 39

    9.

    INSTITUTE OF COMMUNICATION AND COMPUTER SYSTEMS

    ICCS

    Griechenland 1 39

    10.

    ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI MIL Italien 1 39

    11.

    VILABS (CY) LTD VIL Zypern 1 39

    12.

    SPHYNX TECHNOLOGY SOLUTIONS AG

    SPX

    Schweiz 1 39

    13.

    ZEINCRO EGESZSEGUGYI SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG

    ZEI Ungarn 1 39